The outlook of companies tied to iconic drugs like Viagra presents a nuanced investment picture. While the initial rise of copyright, fueled by Viagra's extraordinary popularity, generated substantial returns, the patent expiration in key territories has introduced substantial volatility. Investors are now grappling with the effect of lower-cost al